Influence of Mthfr Polymorphisms on Cardiovascular Risk Markers in Elite Athletes
MTHFR and PON1 polymorphisms are involved in the modulation of plasma levels of homocysteine and oxidated proteins, respectively.
The highest Hcy plasma levels, together with the lowest folates, were observed in MTHFR TT677/AA1298 subjects in both groups.
Growing AOPP plasma concentrations were observed among hurdlers when comparing either MTHFR CT677/AC1298 compound heterozygous or TT677/AA1298 individuals with subjects carrying the other diplotypes.
AOPP were positively correlated with Hcy, and both markers were positively dependent on MTHFR genotype in hurdlers.
To investigate the distribution of MTHFR C677T and A1298C as well as PON1 Q192R gene polymorphisms, known to be involved in hyperhomocysteinemia-related cardiovascular risk, in elite athletes.
Design and Methods
Genetic background at MTHFR and PON1 loci and plasma levels of homocysteine, folate, vitamin B12 and advanced oxidation protein products (AOPP) levels were assessed in thirty-seven 400 m men hurdlers and thirty-four sedentary subjects.
Homocysteine plasma levels and AOPP were significantly higher in hurdlers bearing the TT677/AA1298 diplotype than in both hurdlers and sedentary subjects with other diplotypes. A positive dependence between either homocysteine or AOPP plasma levels and MTHFR, but not PON1 genotype, was observed in hurdlers.
Elite hurdlers, having an unfavourable MTHFR genotype are exposed to increased cardiovascular risk, dependent on alterations of homocysteine and AOPP plasma levels.
- elite athletes;
- cardiovascular risk;
- advanced oxidation protein products;
- gene polymorphisms
Copyright © 2015 Published by Elsevier Inc.
Note to users: Accepted manuscripts are Articles in Press that have been peer reviewed and accepted for publication by the Editorial Board of this publication. They have not yet been copy edited and/or formatted in the publication house style, and may not yet have the full ScienceDirect functionality, e.g., supplementary files may still need to be added, links to references may not resolve yet etc. The text could still change before final publication.
Although accepted manuscripts do not have all bibliographic details available yet, they can already be cited using the year of online publication and the DOI, as follows: author(s), article title, Publication (year), DOI. Please consult the journal's reference style for the exact appearance of these elements, abbreviation of journal names and use of punctuation.
When the final article is assigned to an volumes/issues of the Publication, the Article in Press version will be removed and the final version will appear in the associated published volumes/issues of the Publication. The date the article was first made available online will be carried over.
Autor / Fonte:Monica Currò, Debora Di Mauro, Daniele Bruschetta, Federico D´Amico, Mercurio Vecchio, Fabio Trimarchi, Riccardo Ientile, Daniela Caccamo Clinical Biochemistry 2015 August 14